Ophthalmology Xagena

Xagena Mappa
Xagena Newsletter
Medical Meeting

Wet age-related macular degeneration, Lucentis improves vision

A Phase III clinical trial of the drug Ranibizumab ( Lucentis ) met its primary efficacy endpoint of maintaining vision in patients with wet age-related macular degeneration (AMD ).

Approximately 95 percent of patients maintained or improved vision ( defined as a loss of less than 15 letters in visual acuity ) at one year when treated with Lucentis injections compared to approximately 62 percent of those treated in the control arm ( p